Advantages of predicted phenotypes and statistical learning models in inferring virological response to antiretroviral therapy from HIV genotype

Antiviral Therapy

Volumn 14, Issue 2, 2009, Pages 273-283

  Altmann, André ^a   Sing, Tobias ^a   Vermeiren, Hans ^b   Winters, Bart ^b   Van Craenenbroeck, Elke ^b   Van der Borght, Koen ^b   Rhee, Soo Yon ^c   Shafer, Robert W ^c   Schülter, Eugen ^d   Kaiser, Rolf ^d   Peres, Yardena ^e   Sönnerborg, Anders ^f   Fessel, W Jeffrey ^g   Incardona, Francesca ^h   Zazzi, Mauricio ⁱ   Bacheler, Lee ^j   Van Vlijmen, Herman ^b   Lengauer, Thomas ^a  

^a MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

^b Virco BVBA   (Belgium)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLOGNE   (Germany)

^e IBM RESEARCH   (United States)

^f KAROLINSKA INSTITUTE   (Sweden)

^g KAISER PERMANENTE   (United States)

^h Informa   (Italy)

ⁱ UNIVERSITY OF SIENA   (Italy)

^j VircoLab Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; ZALCITABINE; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

ALGORITHM; ARTICLE; CLASSIFIER; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG RESPONSE; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; RANDOM FOREST; SCORING SYSTEM; STATISTICAL MODEL; BIOLOGICAL MODEL; COMPUTER SIMULATION; DRUG COMBINATION; DRUG EFFECT; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; PREDICTION AND FORECASTING; SEQUENCE ANALYSIS; VIROLOGY;

ALGORITHMS; ANTI-RETROVIRAL AGENTS; COMPUTER SIMULATION; DRUG THERAPY, COMBINATION; HIV; HIV INFECTIONS; HUMANS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PREDICTIVE VALUE OF TESTS; SEQUENCE ANALYSIS;

EID: 67149121192     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Descamps D, Brun-Vezinet F. Benefits of resistance testing. In Geretti AM (Editor). Antiretroviral resistance in clinical practice. London: Mediscript 2006; pp.73-78.
2. Sabin C. Database analyses of predictors of resistance. In Geretti AM (Editor). Antiretroviral resistance in clinical practice. London: Mediscript 2006.
3. Larder B, Wang D, Revell A, et al. The development of artificial neural networks to predict virological response to combination HIV therapy. Antivir Ther 2007; 12:15-24.
4. Altmann A, Beerenwinkel N, Sing T, et al. Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistance. Antivir Ther 2007; 12:169-178.
5. Prosperi M, Di Giambenedetto S, Trotta MP, et al. A fuzzy relational system trained by genetic algorithms and HIV-1 resistance genotypes/virological response data from prospective studies usefully predicts treatment outcomes. Antivir Ther 2004; 9:U89.
6. Prosperi M, Zazzi M, Perno CF, et al. 'Common law' applied to treatment decisions for drug resistant HIV. Antivir Ther 2005; 10:S62.
7. Winters B, Montaner J, Harrigan PR, et al. Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data. J Acquir Immune Defic Syndr 2008; 48:26-34.
8. Draghici S, Potter RB. Predicting HIV drug resistance with neural networks. Bioinformatics 2003; 19:98-107.
9. Jenwitheesuk E, Samudrala R. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach. Antivir Ther 2005; 10:157-166.
10. Shenderovich MD, Kagan RM, Heseltine PN, Ramnarayan K. Structure-based phenotyping predicts HIV-1 protease inhibitor resistance. Protein Sci 2003; 12:1706-1718.
11. Sander O, Sing T, Sommer I, et al. Structural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usage. PLOS Comput Biol 2007; 3:e58.
12. Beerenwinkel N, Daumer M, Sing T, et al. Estimating HIV evolutionary pathways and the genetic barrier to drug resistance. J Infect Dis 2005; 191:1953-1960.
13. Cohen CJ, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16:579-588.
14. Haubrich RH, Kemper CA, Hellmann NS, et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS 2005; 19:295-302.
15. Wegner SA, Wallace MR, Aronson NE, et al. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: Results of the clinical efficacy of resistance testing trial. Clin Infect Dis 2004; 38:723-730.
16. Garcia-Lerma JG, Nidtha S, Blumoff K, Weinstock H, Heneine W. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc Natl Acad Sci U S A 2001; 98:13907-13912.
17. Brun-Vezinet F, Costagliola D, Khaled MA, et al. Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther 2004; 9:465-478.
18. Rosen-Zvi M, Altmann A, Prosperi M, et al. Selecting antiHIV therapies based on a variety of genomic and clinical factors. Bioinformatics 2008; 24:i399-i406.
19. Altmann A, Rosen-Zvi M, Prosperi M, et al. Comparison of classifier fusion methods for predicting response to anti HIV-1 therapy. PLoS One 2008; 3:e3470.
20. Roomp K, Beerenwinkel N, Sing T, et al. Arevir: a secure platform for designing personalized antiretroviral therapies against HIV. Lecture notes in computer science: data integration in the life sciences 2006; 4075:185-194.
21. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006; 20:W13-W23.
22. Meynard JL, Vray M, Morand-Joubert L, et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002; 16:727-736.
23. Van Laethem K, De Luca A, Antinori A, Cingolani A, Perna CF, Vandamme AM. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antivir Ther 2002; 7:123-129.
24. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003; 31:298-303.
25. Vermeiren H, Van Craenenbroeck E, Alen P, et al. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J Virol Methods 2007; 145:47-55.
26. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: fall 2006. Top HIV Med 2006; 14:125-130.
27. DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5:41-48.
28. Breiman L. Random forests. Machine Learning 2001; 45:5-32.
29. Ruschhaupt M, Huber W, Poustka A, Mansmann U. A compendium to ensure computational reproducibility in high-dimensional classification tasks. Stat Appl Genet Mol Biol 2004; 3: Article 37.
30. Beerenwinkel N. Computational analysis of HIV drug resistance data. Aachen: Shaker 2004.
31. Fawcett T. An introduction to ROC analysis. Pattern Recognit Lett 2006; 27:861-874.
32. Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifier performance in R. Bioinformatics 2005; 21:3940-3941.
33. Swanstrom R, Bosch RJ, Katzenstein D, et al. Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects. J Infect Dis 2004; 190:886-893.
34. Svarovskaia ES, Margot NA, Bae AS, et al. Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine. J Acquir Immune Defic Syndr 2007; 46:174-180.